7. Receipt of the last dose of anti-cancer therapy (immunotherapy, endocrine therapy [eg, abiraterone acetate, enzalutamide], targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) </=28 days prior to the first dose of study drug. (With the exception of those treatments described in exclusion #3)